Literature DB >> 25301757

Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.

Christopher R Chapple1, Claus G Roehrborn2, Kevin McVary3, Dapo Ilo4, Carsten Henneges5, Lars Viktrup6.   

Abstract

BACKGROUND: The international prostate symptom score (IPSS) evaluates lower urinary tract symptoms (LUTS) in men with suspected benign prostatic hyperplasia (BPH); the total score does not differentiate between storage and voiding and is unevenly weighted (four questions [57%] on voiding, three questions [43%] on storage).
OBJECTIVE: To evaluate the relative contributions of storage and voiding IPSS subscores to total IPSS at baseline and in response to treatment with tadalafil. DESIGN, SETTING, AND PARTICIPANTS: Integrated analysis of data from four placebo-controlled, 12-wk studies of tadalafil (5mg once daily) in 1499 men with LUTS/BPH. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships between total IPSS and the storage and voiding subscores were assessed using graphical exploration and linear regression modelling. Linear modelling was performed for the baseline and endpoint and for changes in subscores. The optimal storage subscore to total IPSS (S:T) ratio for IPSS improvement was identified using nonparametric regression and gradient-descent optimisation. RESULTS AND LIMITATIONS: The contribution of storage and voiding subscores at baseline and endpoint was 38.8% and 61.2%, and 39.2% and 60.7%, respectively. This intuitive 40:60 storage-to-voiding ratio was similar at baseline and endpoint by treatment group and for changes in subscores, but spanned the entire range for individuals. Changes in total IPSS were greatest for a storage subscore percentage contribution to total IPSS of 42.7%. There was no statistical association between S:T ratio (≥ 40% vs < 40%) at baseline and response to tadalafil. The main limitation was the use of unvalidated storage and voiding IPSS subscores.
CONCLUSIONS: A constant S:T ratio of 4:10 was observed at baseline and endpoint. The greatest effect on total IPSS was noted for an S:T percentage contribution of 42.7%. Tadalafil efficacy was unaffected by the level of storage dysfunction at baseline. PATIENT
SUMMARY: This analysis shows that for men with BPH, improvements during treatment with tadalafil apply to both storage and voiding symptoms at a constant ratio. The extent of storage dysfunction before treatment did not affect the response to treatment.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benign prostatic hyperplasia; International prostate symptom score; Lower urinary tract symptoms; Storage; Tadalafil; Voiding

Mesh:

Substances:

Year:  2014        PMID: 25301757     DOI: 10.1016/j.eururo.2014.08.072

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

Review 1.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

2.  Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study.

Authors:  D Francomano; A Ilacqua; A Cortese; G Tartaglia; A Lenzi; M Inghilleri; A Aversa
Journal:  J Endocrinol Invest       Date:  2016-10-17       Impact factor: 4.256

3.  Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.

Authors:  Kevin Pineault; Shagnik Ray; Andrew Gabrielson; Amin S Herati
Journal:  Transl Androl Urol       Date:  2020-04

4.  Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Boda Guo; Xin Chen; Miao Wang; Huimin Hou; Zhipeng Zhang; Ming Liu
Journal:  Med Sci Monit       Date:  2020-04-24

5.  Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis.

Authors:  Kai Sun; Fengze Sun; Huibao Yao; Dongxu Zhang; Gang Wu; Tianqi Wang; Jipeng Wang; JiTao Wu
Journal:  Am J Mens Health       Date:  2020 Nov-Dec

6.  Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

Authors:  Smita Pattanaik; Ravimohan S Mavuduru; Arabind Panda; Joseph L Mathew; Mayank M Agarwal; Eu Chang Hwang; Jennifer A Lyon; Shrawan K Singh; Arup K Mandal
Journal:  Cochrane Database Syst Rev       Date:  2018-11-16

7.  Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.

Authors:  Ferdinando Fusco; Gianluca D'Anzeo; Carsten Henneges; Andrea Rossi; Hartwig Büttner; J Curtis Nickel
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

8.  Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction.

Authors:  Zhongbao Zhou; Xuesong Zheng; Jitao Wu; Zhenli Gao; Zhunan Xu; Yuanshan Cui
Journal:  Am J Mens Health       Date:  2019 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.